Galderma received a Complete Response Letter (CRL) from the FDA for RelabotulinumtoxinA, its neuromodulator candidate positioned as a Botox alternative. A CRL signals the agency cannot approve the application in its current form and requires additional data or manufacturing corrections before resubmission.
Regulatory
Galderma Gets Complete Response Letter on RelabotulinumtoxinA — What Went Wrong
FDA rejects Galderma's Botox rival on first submission; company faces clinical or manufacturing gaps.
